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Introduction
Mycobacteria-associated skin lesions in cats are cur-
rently classified into three clinical syndromes: feline lep-
rosy, non-tuberculous mycobacteriosis and cutaneous 
tuberculosis caused by Mycobacterium tuberculosis com-
plex (MTBC) members.1 To date about 180 species of 
non-tuberculous mycobacteria (NTM) have been iso-
lated worldwide and >60% of these are known to be 
pathogenic to humans or animals.2,3 Molecular diagnos-
tic techniques represent an important tool for unequivo-
cal identification of agents associated with cutaneous 
mycobacteriosis. These techniques include sequencing 
of multiple genes, for example 16S rRNA, rpoB and 
hsp65, and have shown a high discriminatory power for 
accurate identification of isolated NTM at species level.4,5 
Treatment of disseminated mycobacteriosis in small 
companion animals is challenging and implicates 
potential risk and complications. Particularly, in cases 
where the presence of MTBC members has not been 
ruled out, the owners should be aware of the zoonotic 
potential represented by their infected pets.6 Moreover, 
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therapy requires prolonged antimicrobial administra-
tion and, whenever possible, surgical debulking. In 
geographical areas officially recognised as bovine tuber-
culosis-free, like Switzerland, the risk of cutaneous 
tuberculosis in cats is very low. However, other members 
of the MTBC, for example Mycobacterium microti are, to 
date, recognised as zoonotic pathogens and may affect 
cats.7 Phenotypic susceptibility testing is strongly recom-
mended for pathogens contributing to an infectious pro-
cess that warrants antimicrobial therapy. In particular, 
susceptibility of mycobacterial species to antimicrobials 
cannot be reliably predicted uniquely based on knowl-
edge of their genetic identity.8
Here we report a severe mycobacterial granuloma-
tous dermatitis and panniculitis caused by Mycobacterium 
nebraskense in a cat and the successful surgical and anti-
mycobacterial treatment regimen adopted (Figures 1 
and 2). To our knowledge, this is the first documented 
case of this mycobacteriosis in a cat.
Case description
A 9-year-old male neutered European Shorthair cat was 
referred for nodular skin lesions on the head, which had 
been recognised for 2 weeks. The current owner reported 
that the patient was found as a stray neutered cat 4 
weeks prior to presentation and the previous owner 
remained unknown. Haematological and biochemical 
abnormalities prior to vaccination and dental cleaning 
were anaemia of 26% (reference interval [RI] 30.3–52.3%) 
and hyperglobulinaemia of 55 g/l (RI 28–51 g/l). The 
cat had negative blood test results for feline leukaemia 
virus (FeLV; SNAP FeLV [IDEXX]). The animal was alert 
and responsive during physical examination with a 
body condition score of 5/9 and vital parameters within 
RIs. Several hairless spots on the head and face (Figure 
1a) and, additionally, a 4 × 4 cm nodule cranial to the 
tail base were observed (Figure 2a). Owing to the 
unknown past medical history of the cat, a thoracic and 
abdominal laterolateral survey radiograph was taken 
on which no additional abnormalities were evident. A 
second blood analysis, performed 30 days later, did not 
reveal further abnormalities, apart from the above-
described anaemia and hyperglobulinaemia. Results of 
FeLV and feline immunodeficiency virus tests were still 
negative (SNAP FIV/FeLV Combo Test; IDEXX).
Cytopathological findings of a fine-needle aspira-
tion of the skin nodules on the head were inflammatory 
cell infiltrate with macrophages, lymphocytes, plasma 
cells and eosinophils. An eosinophilic granuloma was 
suspected and the patient was initially treated with 1 
Figure 1 (a) Nodular skin lesions surrounding the base of the right ear and spreading along the right side of the face. (b) The 
first debulking procedure addressed the dorsal nodules on the medial side of the pinna. (c) During the second procedure the 
skin lesions on the side of the face were removed and the defect was closed with a myocutaneous advancement flap. (d) The 
wounds in the head region healed with almost no scar formation and no nodular lesions reappeared 6 months after treatment
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mg/kg prednisolone q24h for 2 weeks. The skin nod-
ules reduced remarkably under treatment but remained 
hairless and recurred immediately to the  initial size 
after discontinuation of the medication. Moreover, 
additional small lesions with similar morphological 
appearance were detected 6 weeks after the start of 
prednisolone treatment at the base of the ears, the lids, 
the left inguinal area and lateral on the left metatarsus. 
Owing to this development, biopsies were taken from 
the base of the left and right ear and sent for histo-
pathological examination.
Histopathological findings were nodular lesions in 
the dermis extending into the upper subcutaneous tis-
sue. The nodules replaced hair follicles and adnexa and 
were partially ulcerated. They consisted of numerous 
epithelioid macrophages, lymphocytes, plasma cells and 
scarce neutrophils (Figure 3a). The described cell infil-
trates were organised in round structures, supported by 
fine fibrous network, forming several granulomas. 
Neither multinucleated giant cells nor caseous necrosis 
was observed. By Ziehl–Neelsen staining, numerous 
acid-fast rod-shaped bacilli were detected within the 
cytoplasm of several epithelioid macrophages (Figure 
3b). Based on the histopathological findings, additional 
biopsies were submitted for mycobacterial culture in 
sterile saline and processed as previously described.9,10
Growth of mycobacteria was first detected on liquid 
media tubes (BBL MGIT; Becton and Dickinson) supple-
mented with PANTA (Polymyxin B, Amphotericin B, 
Nalidixic acid, Trimethoprim, Azlocillin) antibiotic mix-
ture after 3 weeks of incubation at 37°C. Subcultures on 
Middlebrook 7H10 showed growth of scotochromogenic 
colonies after 2 weeks. The sequencing results of 16S 
rRNA, rpoB and hsp65 genes were interpreted as M 
nebraskense species, with identity scores of 1431/1431 bp, 
722/722 bp and 423/424 bp, respectively, compared with 
M nebraskense strain ATCC BAA-837.11 Phenotypic sus-
ceptibility testing was performed using a commercial 
Figure 2 (a) Nodular skin lesions at the tail base. (b) The lesion extending to the spinous processes was excised completely 
and closed with a single pedicle advancement flap. (c) Healing of the surgical incisions was uneventful. Normal growth of hair 
was observed and no nodular lesions reappeared 6 months after treatment
Figure 3 (a) The granulomatous infiltration consisting of numerous epithelioid macrophages, lymphocytes, several plasma 
cells and scarce neutrophils (haematoxylin and eosin stain; scale bar 50 μm). (b) Histological image of the affected skin 
showing myriad rod-shaped red stained intra- and extra-cytoplasmic acid-fast bacteria (Ziehl–Neelsen stain; scale bar 50 μm)
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broth microdilution method for slowly growing NTM 
according to the manufacturer’s instructions (SLOMYCO 
Sensititre; Thermo Fischer Scientific). SLOMYCO 
Sensititre plate was inoculated according to the manu-
facturer’s package insert guidelines and incubated for 14 
days at 37°C under aerobic conditions. The minimal 
inhibitory concentration (MIC) was read manually and 
determined as the lowest concentration of the antibiotic 
showing 100% growth inhibition. As MIC values indicat-
ing resistance for testing M nebraskense are not available, 
interpretative criteria for M kansasii were used for clini-
cal breakpoint interpretation, in accordance with Clinical 
and Laboratory Standards Institute guidelines.12,13 No phe-
notypic resistance was detected for clarithromycin ⩽0.06 
(>16 μg/ml), rifabutin ⩽0.25 (>2 μg/ml), ethambutol 4 
(>4 μg/ml), moxifloxacin ⩽0.12 (>2 μg/ml), rifampin 
⩽0.12 (>1 μg/ml), trimethoprim–sulfamethoxazole 0.25/ 
4.75 (>2/38 μg/ml), amikacin ⩽1 (>32 μg/ml), linezolid 
⩽1 (>16 μg/ml) and ciprofloxacin ⩽0.12 (>2 μg/ml) 
(see Table 1).
Once the diagnosis of granulomatous dermatitis caused 
by mycobacteria was confirmed by histopathological find-
ings, the patient was treated with 10 mg/kg doxycycline 
and 5 mg/kg pradofloxacin PO q24h. In order to suppress 
the accompanying pruritus, hydrocortisone was added 
to the protocol. After 3 weeks of treatment, some of 
the lesions remained unchanged, whereas others had 
increased in size. Although the cat was still in a clinically 
good general condition, a moderate pruritus was observed 
during the course of the described treatment. Succeeding 
the identification of the involved pathogen and based on 
the available literature of mycobacterial treatment, therapy 
was changed to 62.5 mg total dose clarithromycin q12h. 
The pruritus subsided under the treatment with 
clarithromycin. The size of the lesions remained 
unchanged, but they were palpably softer 3 weeks into 
treatment. 
During this period, a decrease in appetite and a 
stiff gait was noticed by the owner. The cat was uncom-
fortable while being caressed over the lower back region. 
During clinical re-examination, lameness of the left fore-
limb was described; in addition, pain during flexion of 
the left carpus and an effusion of the carpal joint was 
palpable. No radiographic abnormality of the bone 
structure was observed. Non-steroidal anti-inflamma-
tory medication (meloxicam 0.05 mg/kg q24h) for 1 
week was added to the therapy regiment and the 
lameness subsided 1 week later. Owing to persistence 
of the skin nodules, a step-wise surgical debulking 
procedure was planned. During the first procedure, 
the nodular lesions around the tail base were removed 
completely. The abnormal tissue extended down to 
the spinous processes of the lumbar vertebrae and 
towards the left lateral aspect of the anal sphincter. 
Wide surgical margins were therefore not feasible. The 
defect was closed with a single pedicle advancement 
flap after lavage and haemostasis (Figure 2b). The 
lesions on the head could only be surgically removed, 
in part, owing to the circular arrangement around the 
right ear (Figure 1b). Despite the narrow margins and 
the remaining microbial granulomas, wound healing 
was uneventful. No spreading of mycobacteria along 
the tissue planes was observed.
The second debulking followed 3 weeks later. Three 
large lesions were removed from the right lateral aspect 
of the face; one of them involving portions of the facial 
nerve. The defect was closed with a single pedicle myo-
cutaneous advancement flap containing part of the 
Table 1 Antimicrobial susceptibility testing performed on the original Mycobacterium nebraskense isolate using a broth 
microdilution method for slowly growing non-tuberculous mycobacteria
Antimicrobial Range (µg/ml) MIC indicating resistance* MIC values measured Interpretation*
Clarithromycin 0.06–64 >16 ⩽0.06 S
Rifabutin 0.25–8 >2 ⩽0.25 S
Ethambutol 0.5–16 >4 4 S
Isoniazid 0.25–8 – 2 –
Moxifloxacin 0.12–8 >2 ⩽0.12 S
Rifampin 0.12–8 >1 ⩽0.12 S
Trimethoprim–sulfamethoxazole 0.12–2.38/8–152 >2/38 0.25/4.75 S
Amikacin 1–64 >32 ⩽1 S
Linezolid 1–64 >16 ⩽1 S
Ciprofloxacin 0.12–16 >2 ⩽0.12 S
Streptomycin 0.5–64 – ⩽0.5 –
Doxycycline 0.12–16 – 1 –
Ethionamide 0.3–20 – 2.5 –
*Minimal inhibitory concentration (MIC) values indicating resistance to testing for Mycobacterium kansasii, according to Clinical and Laboratory 
Standards Institute M24-A2, 2011
S = Susceptible
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platysma (Figure 1c). The right lateral retropharyngeal 
lymph node was clearly increased in size. 
Lymphadenectomy was performed and histological 
examination revealed intracellular acid–fast bacilli. A 
small nodule on the left upper eyelid was removed with 
a wedge excision. Based on the bacteriological diagnosis 
and the performed susceptibly testing, treatment with 75 
mg rifampicin (Sandoz) q24h in addition to clarithromy-
cin was started. After complete healing of the skin inci-
sions on the face, the last remaining nodules on the right 
upper eyelid were removed and the defect was closed 
with a single pedicle advancement flap. One month after 
discontinuation of the antimicrobial the cat was men-
tally alert with a good appetite. By clinical examination, 
9 months after initial presentation and 1 month after ces-
sation of the antibacterials, the cat’s behaviour issues 
and its dermatological lesions were considered resolved. 
All wounds healed with almost no scar formation and 
no nodular lesions reappeared 1 year after treatment 
(Figure 1d, Figure 2c).
Discussion
M nebraskense is a slowly growing non-motile and non-
spore-forming acid–fast bacillus. Mature colonies on 
Middlebrook 7H10 agar plates show a rough appearance 
with an elevated centre and yellow-to-orange pigmenta-
tion under dark conditions (Runyon group II).14 
Previously reported from respiratory specimen from 
humans, M nebraskense is recognised nowadays as a 
potential cause of human infections and, in particular, to 
be associated with pulmonary disease.15–17 Nevertheless 
its primary source and the route of infection remains 
unclear and sporadic isolations from water and abattoir 
environmental samples may suggest a ubiquitous origin 
of this mycobacterium.9,18
Feline cutaneous mycobacteriosis is thought to be the 
result of infected bite or scratch wounds, surgical inter-
ventions or lymphohaematogenous spread of the patho-
gen. In particular, the causative agents of non-tuberculous 
mycobacteriosis are usually divided into rapidly grow-
ing and slowly growing mycobacteria. To date, among 
the rapidly growing NTM, members of the Mycobacterium 
fortuitum and Mycobacterium smegmatis complex,19–21 in 
addition to Mycobacterium alvei,22 Mycobacterium muco-
genicum,23 Mycobacterium septicum23 and Mycobacterium 
thermoresistibile,24 are commonly recognised as patho-
genic species for cats. Furthermore, Mycobacterium 
xenopi,25 Mycobacterium ulcerans,26 Mycobacterium 
szulgai19 and members of the Mycobacterium terrae, 27 
Mycobacterium simiae28 and Mycobacterium avium- 
intracellulare complex23,29 are slow-growing mycobacte-
ria described as potentially pathogenic species for cats. 
Unequivocal identification of these members among the 
genus Mycobacterium is often a challenging task owing 
to their fastidious growth and high genetic similarity 
compared with other microorganisms.30 In some cases, 
laboratory identification of the causal species remains 
impossible and for this reason the management of the 
patient is difficult to predict.1 However, control and 
treatment are often dependent on identification of the 
isolated pathogen. 
As the laboratory reporting time of susceptibility test-
ing results is usually protracted for slowly growing 
mycobacteria, initial empiric antimycobacterial therapy 
is often necessary to impede the spread of the pathogen 
to contiguous tissue compartments. The combination of 
antimycobacterial agents effective against slowly grow-
ing NTM, such as rifampicin, clofazimine or clarithromy-
cin combined with new-generation fluoroquinolones, 
for example moxifloxacin or pradofloxacin, have been 
described as appropriate for killing of the pathogens.31 
Selection of fluoroquinolone monotherapy is a common 
practice for mycobacterial treatment in veterinary medi-
cine and is one of the major causes of treatment failure. 
The reason for this is the capacity of Mycobacteria species 
to rapidly develop mutational resistances against fluoro-
quinolones and should therefore be avoided.31,32 The pre-
sent report shows that the combination of doxycycline 
with pradofloxacin, and at a later stage monotherapy 
with clarithromycin, were not sufficient the treat the 
lesions. In contrast, the resolution of nodular disease was 
achieved by both antimycobacterial drug administration, 
including rifampicin and clarithromycin, in addition to 
surgical excision. In human medicine, treatment guide-
lines for M nebraskense have not been established yet. 
However, one reported case was successfully treated 
with a combination of rifampin and azithromycin.16,17
Even though in the present report not all of the nodu-
lar skin lesions could be removed with wide surgical 
margins, spreading of infection along tissue planes was 
not observed and recurrence of skin disease was not 
detected 1 year after completion of antimicrobial ther-
apy. Standard criteria for selection of patients requiring 
surgical intervention are not available. The more diffi-
cult a NTM pathogen is to treat medically, the more 
advisable it seems to consider surgery in patients with 
large skin nodules. Depending on the size of the lesions, 
partial surgical excision of the nodules may result man-
datory similarly to the described case. Adverse reactions 
due to long-term treatment with clarithromycin and 
rifampicin were mild and self-limiting after discontinua-
tion of the medication. Intermittent vomiting and 
decreased appetite was reported by the owner after 10 
weeks of clarithromycin. Pruritus in the right ear base 
region was observed during rifampicin treatment. In 
addition, the observed lameness of the left forelimb may 
be explained as a drug-induced arthritis due to the pro-
longed therapy with clarithromycin.
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Conclusions
We report the successful treatment of a disseminated 
M nebraskense cutaneous infection in a cat. The initial 
suspect of nodular skin disease of tumorous origin has 
been excluded after identification of acid–fast bacilli and 
growth of NTM in appropriate culture. The infection 
was treated with multiple staged surgical procedures 
and the administration of a combination of antimicrobial 
agents for 12 weeks. Based on the primary sites of the 
lesions, namely the region of the neck and dorsal head, 
cutaneous inoculation of the pathogen as a result of 
infected bite or scratch wounds is suggested. Laboratory 
findings did not raise any suspicion of a compromised 
immune system of the cat.
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